A further series of pyrido[2,3-d]pyrimidine derivatives was synthesized and evaluated against HCT-116, MCF-7, HepG2, and PC-3 cancer cell lines.116 Compounds 13 and 14 showed the most potent anticancer and TS inhibitory activities, surpassing raltitrexed. The gene discussed is TYMS; the disease is cancer.